Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center reported preclinical data supporting an intravesical CAR T-cell strategy for bladder cancer. In a Journal of Experimental Medicine paper, the team engineered CAR T cells targeting MUC16 and demonstrated that catheter-delivered therapy into mouse bladders controlled tumor growth. The study identifies MUC16 as a clinically relevant target for anti-bladder cancer CAR T therapy and highlights the intravesical delivery route as a potentially “easy-to-implement” approach in urologic care. The investigators also frame the rationale around solid-tumor barriers for CAR T cells, including poor infiltration and the risk of off-target toxicity. While the work remains preclinical, it adds to the growing focus on local delivery to improve on-target exposure and reduce systemic exposure for cell therapies in solid tumors.